Neurotoxins · Science from Object Pharma
Aesthetic neuromodulation,reconsideredmolecule by molecule.
Two complementary neurotoxin programs in development, built on science originating from Object Pharma: a bio-comparable program designed around established performance standards, and a bio-better program exploring differentiated characteristics with the potential to advance medical aesthetics.
Neurotoxins · Science from Object Pharma
Bio-Comparable Program
DevelopmentEstablished performance standards
Developing a clinically relevant neurotoxin option designed around established performance standards.
Road to market
01 · Program focus
A clinically relevant neurotoxin option for medical aesthetics, developed to global regulatory standards and pharmaceutical quality expectations.
02 · Scientific rationale
The program builds on established neurotoxin science and development expertise originating from Object Pharma, applied with disciplined pharmaceutical development.
03 · Development status
In development. Further updates will be communicated at appropriate milestones.
Neurotoxins · Science from Object Pharma
Bio-Better Program
DevelopmentDifferentiated characteristics
Exploring differentiated neurotoxin characteristics with the potential to advance medical aesthetics.
Road to market
01 · Program focus
An exploratory program investigating differentiated neurotoxin characteristics, guided by scientific rationale and clinical relevance.
02 · Scientific rationale
Next-generation neurotoxin science originating from Object Pharma provides the foundation for exploring potential differentiation in medical aesthetics.
03 · Development status
In early development. Program details will be shared at appropriate milestones.
Regulatory roadmap
Developed to global and EU standards.
ObNowa's botulinum toxin programs build on science originating from Object Pharma and are advanced through disciplined preclinical and clinical development, designed to meet global regulatory standards.
01
Candidate identification
Candidate engineering, screening and selection.
02
Preclinical development
Characterisation, comparability and safety pharmacology
03
Clinical development
Evaluation of safety and clinical efficacy.
04
Registration
Registration process and preparation for future market entry.
Development status — all programs presented are currently in research and development. Potential indications and applications reflect development objectives and do not represent established efficacy, safety or regulatory approval.
Work with us
Develop the nextaesthetic neuromodulatorwith us.
Licensing, clinical development and commercial partnerships across the neurotoxin programs.